Skip to the main content.

Newsroom

KBI's Leadership Team Discusses Operational Consolidation with Selexis at BIO International 2023

The recent operational consolidation of KBI Biopharma, Inc. and Selexis SA brings a streamlined approach to support customers in rapidly accelerating drug development and manufacturing. We caught up with Tim Lowery, President at JSR Life Sciences,...

Read More

KBI Biopharma Unveils KBI PUREplatform™, a Game-Changing Microbial Expression Offering to Redefine Biopharmaceutical Manufacturing

Platform leverages proprietary PUREcoli™ strain and cutting-edge screening packages for unmatched efficiencies and optimized production processes...

Read More

JSR Life Sciences Announces Operational Consolidation of KBI Biopharma, Inc. and Selexis SA to Operate as one Organization, Providing Seamless Experience for Partners

KBI’s new model will enhance operational efficiencies, drive strategic clarity, and accelerate innovation for global biopharma customers Sunnyvale,...

Read More

KBI Biopharma Appoints Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer

Durham, North Carolina (May 10, 2023) – KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced the appointment of Marykay...

Read More

KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

Durham, North Carolina (April 17, 2023) – KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment...

Read More

KBI Biopharma, Inc. Releases Inaugural FIH Manufacturing Batch at Integrated Switzerland Facility Five Months After Opening

Milestone affirms KBI and Selexis SA’s Geneva cGMP site is operational and running successfully. GENEVA, March 21, 2023 – KBI Biopharma, Inc. (KBI),...

Read More

KBI Biopharma Announced as 2023 ISPE Facility of the Year Submission Finalist

KBI Biopharma is thrilled to announce that Patriot Park has been named a finalist in the 2023 ISPE Facility of the Year Awards (FOYA) in two...

Read More

KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment

Following the recent Sudan ebolavirus outbreak in Uganda, KBI is providing emergency support through global production efforts. DURHAM, NC (January...

Read More

KBI Biopharma, Inc. Secures Swissmedic Regulatory Establishment License for State-of-the-Art Mammalian Cell Manufacturing Facility in Geneva

Major regulatory milestone demonstrates compliance with stringent standards for cGMP drug substance manufacturing. GENEVA, December 20, 2022– KBI...

Read More

A Look Back at 2022

What a year 2022 turned out to be! It was a year of growth and expansion, from the launch of our new KBI commercial manufacturing facility in...

Read More

Never Miss Another Update! 

Subscribe to KBI's Newsletter, The Pulse, to stay up-to-date on all the latest news, articles, and events from KBI Biopharma.